These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 17267695

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD, Kelly B, Oto A, Jesse M, Aristimuno P, Ernst R, Chaljub G.
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [Abstract] [Full Text] [Related]

  • 3. Are patients with moderate renal failure at risk for developing nephrogenic systemic fibrosis?
    Saab G, Abu-Alfa A.
    Radiology; 2007 Sep; 244(3):930-1; author reply 931-2. PubMed ID: 17709844
    [No Abstract] [Full Text] [Related]

  • 4. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
    Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER, Semelka RC.
    Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
    [Abstract] [Full Text] [Related]

  • 5. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide.
    Bruce R, Wentland AL, Haemel AK, Garrett RW, Sadowski DR, Djamali A, Sadowski EA.
    Invest Radiol; 2016 Nov; 51(11):701-705. PubMed ID: 26885631
    [Abstract] [Full Text] [Related]

  • 6. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?
    Nandwana SB, Moreno CC, Osipow MT, Sekhar A, Cox KL.
    Radiology; 2015 Sep; 276(3):741-7. PubMed ID: 25875973
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities.
    Wertman R, Altun E, Martin DR, Mitchell DG, Leyendecker JR, O'Malley RB, Parsons DJ, Fuller ER, Semelka RC.
    Radiology; 2008 Sep; 248(3):799-806. PubMed ID: 18632533
    [Abstract] [Full Text] [Related]

  • 10. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
    Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, Abujudeh HH.
    Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
    [Abstract] [Full Text] [Related]

  • 11. Nephrogenic systemic fibrosis: possible association with a predisposing infection.
    Golding LP, Provenzale JM.
    AJR Am J Roentgenol; 2008 Apr; 190(4):1069-75. PubMed ID: 18356457
    [Abstract] [Full Text] [Related]

  • 12. Incidence of nephrogenic systemic fibrosis at two large medical centers.
    Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, DeLapaz RL, Lee HJ, Magro CM, Valeri AM.
    Radiology; 2008 Sep; 248(3):807-16. PubMed ID: 18710976
    [Abstract] [Full Text] [Related]

  • 13. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR.
    Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
    [Abstract] [Full Text] [Related]

  • 14. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
    Soulez G, Bloomgarden DC, Rofsky NM, Smith MP, Abujudeh HH, Morgan DE, Lichtenstein RJ, Schiebler ML, Wippold FJ, Russo C, Kuhn MJ, Mennitt KW, Maki JH, Stolpen A, Liou J, Semelka RC, Kirchin MA, Shen N, Pirovano G, Spinazzi A.
    AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
    [Abstract] [Full Text] [Related]

  • 15. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort.
    Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, Simpson K, Roditi GH.
    Radiology; 2007 Oct; 245(1):168-75. PubMed ID: 17704357
    [Abstract] [Full Text] [Related]

  • 16. Nephrogenic systemic fibrosis: center case review.
    Lauenstein TC, Salman K, Morreira R, Tata S, Tudorascu D, Baramidze G, Singh-Parker S, Martin DR.
    J Magn Reson Imaging; 2007 Nov; 26(5):1198-203. PubMed ID: 17969162
    [Abstract] [Full Text] [Related]

  • 17. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
    Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ.
    Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279
    [Abstract] [Full Text] [Related]

  • 18. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan).
    Khurana A, Runge VM, Narayanan M, Greene JF, Nickel AE.
    Invest Radiol; 2007 Feb; 42(2):139-45. PubMed ID: 17220732
    [Abstract] [Full Text] [Related]

  • 19. Incidence of immediate gadolinium contrast media reactions.
    Prince MR, Zhang H, Zou Z, Staron RB, Brill PW.
    AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
    [Abstract] [Full Text] [Related]

  • 20. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis.
    Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P.
    Br J Dermatol; 2008 Feb; 158(2):273-80. PubMed ID: 18067485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.